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Guidelines
AbstrAct 
The following is a summary of the recommendations and 
good practice points for the BTS Guideline for the initial 
outpatient management of pulmonary embolism. Please refer 
to the full guideline for full information about each section. 
IntroductIon
The full guideline for the initial outpatient 
management of pulmonary embolism (PE) is 
published in Thorax.1 The key features of the 
guideline are highlighted in a short article 
published to accompany the full guideline.2 
The following is a summary of the recommen-
dations and good practice points (GPPs). The 
sections referred to in the summary refer to the 
full guideline.
bAckground
The British Thoracic Society (BTS) Guide-
line for the initial outpatient management of 
PE provides guidance on how to risk-stratify 
patients with suspected and confirmed PE and 
subsequently manage them in an outpatient or 
ambulatory care setting.
Over the last 10 years there has been an 
increasing drive to manage many conditions 
traditionally treated during an inpatient 
admission as outpatients. This has become 
widespread practice in managing deep vein 
thrombosis, and data are increasing to support 
this strategy in PE. With the licensing of the 
direct oral anticoagulants (DOACs) for the 
treatment of acute PE which do not require a 
low-molecular-weight heparin (LMWH) run-in 
or International Normalised Ratio (INR) moni-
toring, outpatient management of suspected 
PE has become more straightforward. This is 
clearly an opportunity to improve patient expe-
rience and reduce hospital length of stay, but 
it also presents a risk if the wrong patients are 
identified for outpatient management.
Many acute hospital trusts have begun 
outpatient management of both suspected 
and confirmed PE, as evidenced by the large 
number of abstracts presented at conference 
proceedings, in addition to peer-reviewed 
publications. However, it is readily apparent 
from these reports that practice varies, and it is 
of concern that in some units no validated risk 
assessment is being undertaken. Given that PE 
can be fatal, this raises concerns over the safety 
of some local protocols. This safety concern 
is further highlighted by the fact that a study 
of outpatient management of PE was termi-
nated early by the Drug and Safety Monitoring 
Board after two deaths in the outpatient arm 
(one right ventricular thrombus and one fatal 
bleed).3
The National Institute for Health and Care 
Excellence guidelines on the management of 
thromboembolic diseases published in 2012 
and updated in 2015 provided no recommen-
dations on how to risk-stratify for outpatient 
management.4 While both the European 
Society of Cardiology and the American College 
of Chest Physicians have also published guid-
ance on the management of acute PE which 
both support outpatient management, neither 
provides detailed practical recommendations 
on risk stratification.5–7
Finally, the advent of the DOACs facilitates 
early discharge from hospital since patients no 
longer need to be kept in hospital until they 
have reached a therapeutic INR. This raises 
the question of how to identify moderate-risk 
patients appropriate for early discharge.
In conclusion, there is a need for a stan-
dardised approach to identify low-risk patients 
for outpatient management and also to aid 
clinicians in deciding when moderate-risk 
patients can be discharged early. The aim of 
this guideline is to standardise the approach 
to the initial outpatient management of PE 
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(up to 3 weeks post diagnosis) and to reduce the risk to 
patients and hospital trusts, while ensuring best value to the 
National Health Service.
target audience for the guideline
This guideline is aimed at clinicians, in particular physi-
cians, clinical nurse specialists and advanced nurse prac-
titioners, at all levels of seniority delivering emergency, 
acute, ambulatory and inpatient care who are involved in 
the management of acute PE. The main specialties refer-
ring to the guidance are likely to be acute, emergency, 
general (internal) and respiratory medicine. It is also 
designed to inform general practitioners involved in the 
delivery of ambulatory care or thrombosis pathways. This 
document may also be used by healthcare commissioners 
and hospital management to ensure appropriate staffing 
and resourcing of ambulatory care facilities to integrate PE 
management into ambulatory care pathways.
scope of the guideline
The guideline covers
 – adults (≥16 years) with suspected and confirmed acute 
PE;
 – haemodynamically stable PE;
 – use of DOACs in relation to suspected PE and outpa-
tient management;
 – risk stratification for identifying patients suitable for 
outpatient management or early discharge;
 – special subgroups of patients (pregnant patients, those 
with cancer and intravenous drug abusers).
The guideline does not cover
 – the diagnostic algorithm for PE;
 – evidence for cancer screening;
 – detailed comparisons of anticoagulant drugs;
 – who should be treated and not treated, specifically 
how to manage subsegmental PE;
 – duration of anticoagulation and thrombophilia 
investigations.
Methodology
This guideline is based on the best available evidence. 
The methodology used to write the guideline adheres 
strictly to the criteria as set by the AGREE II collabora-
tion, which is available online at http://www. agreetrust. 
org/ resource- centre/ agree- ii/. The BTS Standards of 
Care Committee (SOCC) guideline production manual is 
available at https://www. brit- thoracic. org. uk/ standards- of- 
care/ guidelines/.
clinical questions and literature search
Clinical questions were structured in the Population, Inter-
vention, Control, Outcome format (see online supplemen-
tary web appendix 1) to define the scope of the guideline 
and inform the literature search.
Systematic electronic database searches were conducted 
in order to identify potentially relevant studies for inclu-
sion in the guideline. For each topic area the following 
databases were searched: Ovid MEDLINE (including 
MEDLINE In Process), Ovid EMBASE and the Cochrane 
Library (including the Cochrane Database of Systematic 
Reviews and the Database of Abstracts of Reviews of Effects) 
from 1980.
The searches were first run in July 2014 and updated in 
October 2015 (see online supplementary web appendix 
1 for search strategy). Searches included a combination 
of indexed terms and free-text terms and were limited to 
English-language publications only. The initial search iden-
tified 2385 potential abstracts and the second search 432 
other abstracts.
Appraisal of literature
Appraisal was performed to be compliant with the AGREE 
II instrument. Two individuals (LH, RP) read the title and 
abstract of each article retrieved by the literature searches 
and decided whether the paper was definitely relevant, 
possibly relevant or not relevant to the project. Criteria 
formulated for categorising the abstracts into these three 
groups were
 – whether the study addressed the clinical question;
 – whether the appropriate study type was used to 
produce the best evidence to answer the clinical 
question;
 – review articles were excluded;
 – abstract was in English.
Abstracts were not rejected on the basis of the journal 
of publication, the country in which the research was 
performed or published or the date of publication.
The screened abstracts were allocated to the relevant 
section(s) of the guideline and two group members allo-
cated to each of those sections. The full paper was obtained 
for all relevant or possibly relevant abstracts.
The first screening process identified 153 of the initial 
2385 reference abstracts to be definitely or possibly rele-
vant to the guideline. Two guideline reviewers per section 
independently reviewed the abstracts to identify papers 
to be appraised for the guideline. The two reviewers for 
each section then independently appraised each paper 
assigned to them using the Scottish Intercollegiate Guide-
lines Network (SIGN) critical appraisal checklists. The reli-
ability of the evidence in each individual study was graded 
using the SIGN critical appraisal check lists and is shown 
in the evidence tables (++, + or –). The body of evidence 
for each recommendation was summarised into evidence 
statements and graded using the SIGN grading system (see 
table 1).
Disagreements were resolved by discussion with the 
section partner. The second literature search in October 
2015 yielded 432 abstracts. Of these, 13 were identified as 
definitely or possibly relevant to the guideline. However, all 
of the pertinent ones from this search had been identified 
by the Guideline Development Group (GDG) in the mean-
time and already incorporated.
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considered judgement and grading of evidence
The GDG used the evidence tables to judge the body of 
evidence and grade recommendations for this guideline. 
The evidence tables are available in online supplementary 
web appendix 2. Where evidence was lacking to answer 
the formulated clinical questions, expert opinions were 
obtained through consensus. The following were consid-
ered in the grading of the recommendations:
 – the available volume of the body of evidence;
 – how applicable the obtained evidence was in making 
recommendations for the defined target audience of 
this guideline;
 – whether the evidence was generalisable to the target 
population for the guideline;
 – whether there was a clear consistency in the evidence 
obtained to support recommendations;
 – what the implications of recommendations would be 
on clinical practice in terms of resources and skilled 
expertise.
Cost-effectiveness was not reviewed in detail as in-depth 
economic analysis of recommendations falls beyond the 
scope of this guideline.
Recommendations were graded from A to D, as indicated 
by the strength of the evidence, as in table 2. In line with 
SIGN guidance, evidence appraised as ‘minus’ was consid-
ered in context but in the absence of other supporting 
evidence appraised as ‘plus’, it was discussed among the 
GDG regarding that point and any recommendation hence 
made was grade D. Important practical points currently 
lacking any research evidence and assessed as unlikely to 
have research evidence in the future were highlighted as 
GPPs.
drafting the guideline
The GDG corresponded regularly by email, and meetings 
of the full group were held in April and October 2014, 
March, May and October 2015, and January 2016 as well 
as a number of teleconferences. The BTS SOCC reviewed 
the draft guideline in March 2016. The draft guideline was 
Table 1 Key to evidence statements
Grade Evidence
1++ High-quality meta-analyses, systematic reviews of RCTs or RCTs with a very low risk of bias
1+ Well-conducted meta-analyses, systematic reviews of RCTs or RCTs with a low risk of bias
1− Meta-analyses, systematic reviews of RCTs or RCTs with a high risk of bias
2++ High-quality systematic reviews of case–control or cohort studies or high-quality case–control or cohort studies with 
a very low risk of confounding, bias or chance and a high probability that the relationship is causal
2+ Well-conducted case–control or cohort studies with a low risk of confounding, bias or chance and a moderate 
probability that the relationship is causal
2− Case–control or cohort studies with a high risk of confounding, bias or chance and a significant risk that the 
relationship is not causal
3 Non-analytic studies, eg, case reports, case series
4 Expert opinion
RCT, randomised controlled trial.
Table 2 Grades of recommendations
Grade Type of evidence
A At least one meta-analysis, systematic review or RCT rated as 1++ and directly applicable to the target population or
A systematic review of RCTs or a body of evidence consisting principally of studies rated as 1+ directly applicable to 
the target population and demonstrating overall consistency of results.
B A body of evidence including studies rated as 2++ directly applicable to the target population and demonstrating 
overall consistency of results or
Extrapolated evidence from studies rated as 1++ or 1+.
C A body of evidence including studies rated as 2+ directly applicable to the target population and demonstrating 
overall consistency of results or
Extrapolated evidence from studies rated as 2++.
D Evidence level 3 or 4 or.
Extrapolated evidence from studies rated as 2+.
✔ Important practical points for which there is no research evidence, nor is there likely to be any research evidence. 
The guideline committee wishes to emphasise these as good practice points.
RCT, randomised controlled trial.
copyright.











es: first published as 10.1136/bm




4 Howard LS, et al. BMJ Open Resp Res 2018;5:e000281. doi:10.1136/bmjresp-2018-000281
Open access
made available online in January/February 2017 for public 
consultation and circulated to all the relevant stakeholders. 
The BTS SOCC re-reviewed the revised draft guideline 
in June 2017, and final SOCC approval was granted in 
December 2017.
This BTS Guideline will be reviewed within 5 years of 
publication.
declarations of interest
All members of the Guideline Group made declarations of 
interest in line with BTS Policy, and further details can be 
obtained on request from BTS. GDG members are listed in 
Appendix 1 to the full guideline.
representation and stakeholder organisations
Dr Vincent Connolly represented the Society for Acute 
Medicine; Dr Chris Davies represented the Royal College 
of Physicians, London; Dr Daniel Horner and Dr Laura 
Hunter represented the Royal College of Emergency 
Medicine; Ms Wendy Preston represented the Association 
of Respiratory Nurse Specialists; Dr Campbell Tait repre-
sented the British Committee for Standards in Haema-
tology.
summary of recommendations
Outcomes of outpatient care for low-risk PE
Recommendations
 ► Patients with PE should be assessed for suitability for 
management as outpatients. Grade B
 ► Patients assessed as low risk and suitable for outpa-
tient management should be offered treatment in an 
outpatient setting where a robust pathway exists for 
follow-up and monitoring. Grade B
Research recommendation
Research is required to enhance the evidence base 
regarding patient experience and cost effectiveness.
Inclusion and exclusion criteria for outpatient management or 
early discharge
See figure 1a and 1b and tables 3, 4, 5, 6 and box 1.
Figure 1 Algorithm for the outpatient management of pulmonary embolism (PE).*If imaging cannot be undertaken same 
day, then patients may be considered for empirical treatment with either low-molecular-weight heparin or apixaban 
or rivaroxaban and asked to return within 24 hours for definitive diagnosis, providing they fulfil the remainder of the 
criteria for outpatient management. †Patients with cancer or those who are pregnant or within 6 weeks post partum 
may be considered for outpatient management. BNP, B-type natriuretic peptide; NICE, National Institute for Health 
and Care Excellence; NT-proBNP, N-terminal B-type natriuretic peptide; PESI, Pulmonary Embolism Severity Index; 
sPESI, simplified PESI; RV, right ventricular.
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Recommendations
 ► Patients with confirmed PE should be risk-stratified 
using a validated clinical risk score. Grade B
 ► Patients in Pulmonary Embolism Severity Index 
(PESI) Class I/II, simplified PESI (sPESI) 0 or 
meeting the Hestia criteria should be considered for 
outpatient management of PE. Grade B.
 ► Where PESI or sPESI is used and indicates a low risk, a 
set of exclusion criteria should be applied to patients 
being considered for outpatient management of 
confirmed PE. Grade B
 – Exclusion criteria include
 – Haemodynamic instability (HR >110; systolic 
blood pressure <100 mm Hg; requirement for 
inotropes and critical care; requirement for 
thrombolysis or embolectomy).
 – Oxygen saturations <90%  on air.
 – Active bleeding or risk of major bleeding (eg, 
recent gastrointestinal bleed or surgery, previ-
ous intracranial bleeding, uncontrolled hyper-
tension).
 – On full-dose anticoagulation at the time of the 
PE.
 – Severe pain (eg, requiring opiates).
 – Other medical comorbidities requiring hospital 
admission.
 – Chronic kidney disease stages 4 or 5 (estimated 
glomerular filtration rate <30 mL/min) or se-
vere liver disease.
 – Heparin-induced thrombocytopenia within the 
last year and where there is no alternative to re-
peating heparin treatment.
 – Social reasons which may include inability to 
return home, inadequate care at home, lack of 
telephone communication, concerns over com-
pliance, etc.
 ► No specific assessment of bleeding risk is required 
in patients who are deemed low risk by PESI/sPESI/ 
Hestia criteria. Grade B
 ► Measurement of right ventricular:left ventricular ratio 
on CT or assessment of right ventricular function on 
echocardiography is not obligatory for the identifica-
tion of low-risk patients for outpatient management. 
Grade C
 ► Where right ventricular dilatation has been identified 
on CT scanning or echocardiography in patients who 
are suitable for outpatient management, consider 
measuring laboratory cardiac biomarkers (B-type 
natriuretic peptide (BNP), N-terminal B-type natriu-
retic peptide, high-sensitivity troponin I or high-sen-
sitivity troponin T). Normal values may be used to 
identify low-risk patients; elevated biomarkers in this 
context should prompt inpatient admission for obser-
vation. Grade C
Good practice point
 ✔ In the context of low-risk PE and an incidental find-
ing of elevated troponin, senior review is required 
and alternative causes for troponin release should be 
considered.
Management of patients with suspected PE, where a diagnosis 
has yet to be confirmed
Recommendation
 ► Patients with suspected PE should, where reasonably 
practical, undergo investigation on the same day of 
presentation to exclude a diagnosis of PE. An alterna-
tive strategy of anticoagulation followed by outpatient 
imaging within 24 hours may be considered in patients 
with suspected PE, who have been deemed low risk 
and eligible for outpatient care as per confirmed PE. 
Robust systems should be in place to facilitate next 
day investigation and review. Grade D
Treatment of suspected/confirmed PE in the outpatient setting
(See tables 7 and 8).
Recommendations
 ► Patients with confirmed PE being treated in the 
outpatient setting should be offered treatment with 
either LMWH and dabigatran, LMWH and edoxaban 
or a single-drug regimen (apixaban or rivaroxaban). 
Grade A
 ► Patients with suspected PE being treated in the outpa-
tient setting may be treated with apixaban or rivarox-
aban pending diagnosis as an alternative to LMWH. 
Grade D
Good practice point
 ✔ Using a single DOAC in a pathway is preferred to 
minimise potential confusion over dosing and admin-
istration.
Assessing patients transitioning from inpatient care to early 
discharge/outpatient care?
Recommendation
 ► Patients who have been admitted with an interme-
diate risk PE (PESI Class III) can be considered for 
early discharge when they meet the criteria for low 
risk (PESI class I/II or sPESI score 0). Grade C
Good practice points
 ✔ Those with PESI-48 class III or sPESI-48 score of >0 
are considered to be at higher risk of adverse out-
come and senior review is necessary prior to dis-
charge; PESI and sPESI may remain elevated due to 
non-reversible factors (eg, cancer, age) which should 
be taken into consideration when using clinical 
judgement.
 ✔ Consideration should be given to repeating assess-
ment of right ventricular function with echocardi-
ography or biomarkers in those admitted with right 
ventricular dysfunction or biomarker elevation at 
baseline.
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Level of seniority of review
Good practice points
 ✔ Patients with confirmed or suspected PE should be re-
viewed by a consultant prior to discharge on an out-
patient PE pathway. If no consultant is available, then 
patients may be reviewed by a senior trainee (ST3 or 
above; ST4 in the case of emergency medicine) by a 
staff grade or similar substantive career grade doctor, 
advanced nurse practitioner or clinical nurse special-
ist designated to undertake this role within the de-
partment with consultant advice available.
 ✔ If patients are on an outpatient pathway for suspect-
ed PE and being considered for discharge and scan-
ning the following day, a local protocol should be in 
place to guide a full cardiorespiratory assessment to 
exclude other causes for symptoms (including full 
history, examination, ECG and chest radiograph), in-
cluding risk assessment.
Follow-up of patients specific to those managed in the outpatient 
setting
Recommendations
 ► Patients with confirmed PE who are eligible for 
outpatient care should be provided with verbal and 
written information on the signs and symptoms of 
recurrence, major bleeding and additional compli-
cations. Individual centres should also provide an 
appropriate point of contact in the event of complica-
tions or concerns, both in and out of hours. Grade B
 ► Patients should have a formal review (telephone/
face to face) at least once during the first week after 
discharge to ensure therapeutic compliance along 
with the absence of complications. Grade B
 ► Hospitals should have local protocols and pathways in 
place for follow-up of all PE patients, whether treated 
as an inpatient or outpatient. This should include 
assessment of ongoing symptoms (with further 
directed investigation as appropriate) and consider-
ation of optimal duration/modality of anticoagula-
tion. Grade D
Good practice points
 ✔ Consider initial assessment of provoking risk factors 
for the index PE at an early stage, for example, im-
mobility, surgery, cancer, intercurrent illness, etc, 
since this will determine duration of anticoagulation. 
Screening policies for malignancy are out of scope for 
this guideline, but when screening investigations are 
performed, a mechanism should be in place to review 
results within a prompt time frame.
 ✔ Follow-up of PE should be performed by clinicians 
with a special interest in venous thromboembolism.
Research recommendation
Further studies evaluating the role of technology for 
remote monitoring, such as virtual consultations and data 
gathering, are needed.




 ✔ All pregnant and postpartum women presenting with 
suspected PE or confirmed PE should be reviewed by 
a consultant and discussed with maternity services pri-
or to discharge.
 ✔ Outpatient care pathways may be considered for sus-
pected or confirmed PE in pregnancy and/or the 
postpartum period.
 ✔ Clinical risk scores derived for non-pregnant patients, 
such as PESI/sPESI, should not be used in pregnant 
women.
 ✔ DOACs or Vitamin K antagonists should not be used 
in pregnant patients with suspected or proven PE.
Research recommendation
Studies addressing the safety and efficacy of outpatient 
care pathways for pregnant and postpartum patients with 
suspected or confirmed PE are needed.
Cancer
Recommendation
 ► The Hestia criteria may be used to evaluate patients 
with active cancer for suitability for outpatient 
management of PE. Grade D
Good practice points
 ✔ Patients with active cancer should be reviewed by a 
consultant prior to discharge given the higher risk of 
30-day mortality. Good practice point
 ✔ Patients with incidental PE should be managed in the 
same way with respect to outpatient management as 
those with symptomatic PE.
Research recommendation
Further studies are needed to validate risk stratification 
tools specific to patients with cancer.
Intravenous drug use
Good practice point
 ✔ Intravenous drug abusers with suspected PE should 
be admitted for further investigation and manage-
ment.
Patient information and support needs
Recommendation
 ► Written patient information and education should be 
integral to outpatient PE pathways. Grade D
Good practice point
 ✔ Succinct written information should be provided to 
the patient on discharge, using non-technical lan-
guage and including telephone numbers/email ad-
dresses for advice on dealing with any subsequent 
changes in the patient’s condition. An example, 
from Sheffield Teaching Hospitals, is included in 
online appendix 3. The information material pro-
duced by the thrombosis charity Thrombosis UK 
(http://www. thrombosisuk. org) may also prove 
helpful.  
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Table 3 Pulmonary Embolism Severity Index
Parameter Score Risk class Total points


























  Age Age in years
  Male sex +10
Comorbid conditions
  Cancer +30
  Heart failure +10
  Chronic lung disease +10
Clinical findings
  Pulse≥110 bpm +20
  SBP<100 mm Hg +30
  RR≥30/min +20
  Temp<36°C +20
  Altered mental status* +60
  Arterial blood oxygen saturation<90%† +20
*Defined as disorientation, lethargy, stupor or coma.
†With or without the administration of supplemental oxygen.
RR, respiratory rate; SBP, systolic blood pressure.
Table 4 Simplified Pulmonary Embolism Severity Index
Parameter Score Risk class Total points




Chronic cardiopulmonary disease 1
Pulse≥110 bpm 1
SBP<100 mm Hg 1
Arterial blood oxygen saturation<90%† 1
*Defined as active cancer (diagnosed within last 12 months or undergoing treatment, personal communication from Prof David Jimenez).
†With or without the administration of supplemental oxygen.
SBP, systolic blood pressure.
Table 5 Geneva score
Parameter Score Risk class Total points
Cancer 2 Low ≤2
Heart failure 1 High >2
Previous DVT 1
SBP<100 mm Hg 2
PaO2<8 kPa (60 mm Hg) 1
DVT confirmed on USS 1
DVT, deep vein thrombosis; SBP, systolic blood pressure; USS, ultrasound.
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Table 6 Clinical exclusion criteria for outpatient pulmonary embolism (PE) management
Hestia criteria (Zondag et al)8 Davies et al9
Is the patient haemodynamically unstable?* Yes/no Need for hospitalisation for another 
medical reason
Yes/no
Is thrombolysis or embolectomy necessary? Yes/no Additional monitoring required (ECG, 
oxygen, parenteral analgesia)
Yes/no
Active bleeding or high risk of bleeding?† Yes/no Likelihood of poor compliance/
difficulty with follow-up
Yes/no
More than 24 hours of oxygen supply to maintain 
oxygen saturation>90%?
Yes/no Previous PE/early recurrence of PE Yes/no
Is PE diagnosed during anticoagulant treatment? Yes/no Coexisting major DVT Yes/no
Severe pain needing intravenous pain medication 
for>24 hours?
Yes/no Bleeding disorders, active bleeding Yes/no
Medical or social reason for treatment in 
hospital>24 hours?
Yes/no Pregnancy Yes/no
Does the patient have a creatinine clearance<30 
mL/min?
Yes/no Patient preference for hospital stay Yes/no
Does the patient have severe liver impairment? 
(discretion of clinician)
Yes/no
Is the patient pregnant? Yes/no
Does the patient have a documented history of 
heparin-induced thrombocytopenia?
Yes/no
Eligible for outpatient treatment: no risk factors
Ineligible for outpatient treatment: at least one risk factor present
*SBP <100 mm Hg with HR >100 bpm; condition requiring admission to intensive care unit.
†Gastrointestinal bleeding in the preceding 14 days, recent stroke (<4 weeks ago), recent operation (<2 weeks ago), bleeding disorder, 
thrombocytopenia (platelet count <75×109/L), uncontrolled hypertension (SBP >180 mm Hg or DBP >110 mm Hg).
DVT, deep vein thrombosis; SBP, systolic blood pressure.
Table 7 Key randomised trials of direct oral anticoagulants in the treatment of acute pulmonary embolism (PE)
Study patients (n) 
Treatment arm (vs heparin/
warfarin) Efficacy Safety
(study drug vs warfarin) 
RE-COVER (2009)
n=2564
LMWH≥5 days followed by 
dabigatran 150 mg twice daily
Recurrent VTE or fatal PE: 
2.4% vs 2.1%
Major bleeding: 1.6% vs 1.9%
RE-COVER II (2014)
n=2589
LMWH≥5 days followed by 
dabigatran 150 mg twice daily
Recurrent VTE or fatal PE: 
2.3% vs 2.2%




Rivaroxaban 15 mg twice daily for 
3 weeks followed by 20 mg once 
daily
Recurrent VTE or fatal PE: 
2.1% vs 1.8%




Apixaban 10 mg twice daily for 
7 days followed by 5 mg twice daily
Recurrent VTE or fatal PE: 
2.3% vs 2.7%
Major bleeding: 0.6% vs 1.8%
HOKUSAI-VTE (2013)
n=8292
LMWH≥5 days followed by 
edoxaban 60 mg once daily 
(30 mg once daily if creatinine 
clearance 30–50 mL/min or body 
weight<60 kg)
Recurrent VTE or fatal PE: 
3.2% vs 3.5%
Major or CRNM bleeding: 8.5% 
vs 10.3%
*Only EINSTEIN PE included exclusively patients with PE.
CRNM, clinically relevant non-major; LMWH, low-molecular-weight heparin.
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Healthcare providers need to use clinical judgement, knowl-
edge and expertise when deciding whether it is appropriate to 
apply recommendations for the management of patients. The 
recommendations presented here are a guide and may not be 
appropriate for use in all situations. The guidance provided 
does not override the responsibility of healthcare professionals to 
make decisions appropriate to the circumstances of each patient, 
in consultation with the patient and/or their guardian or carer. 
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Table 8 Relative risk of major and non-major bleeding 
using direct oral anticoagulants compared with Vitamin K 
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Study Drug
Risk ratio of major 
and clinically relevant 
non-major bleeding 
events
















DVT, deep vein thrombosis; VTE, venous thromboembolism. 
box 1 Clinical exclusion criteria (Aujesky et al (2011))10
Exclusion criteria
 ► Oxygen saturation<90%
 ► Systolic blood pressure <100 mm Hg
 ► Chest pain needing opiates
 ► Active bleeding
 ► High risk of bleeding (stroke within the preceding 10 days, gastroin-
testinal bleed within the last 14 days or platelet count<75 000/mm3)
 ► Obesity (weight>150 kg)
 ► Heparin-induced thrombocytopenia 
 ► Severe renal failure (creatinine clearance<30 mL/min)
 ► Therapeutic anticoagulation (International Normalised Ratio ≥2.0)
 ► Barriers to treatment adherence or follow-up
copyright.
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